ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2135

Synovial Fluid High-density Lipoprotein (HDL)-miR-1246 Is Enriched in Patients with Inflammatory Arthritis Compared to Osteoarthritis and Increases Synovial Fibroblast IL-6 Expression

Olivia Posey1, Qiong Wu1, Anastasiia Phothisane1, Christine Pham2, Deborah Parks2, Antonina Akk3, Danielle Michell1, Kasey Vickers1 and Michelle Ormseth1, 1Vanderbilt University Medical Center, Nashville, TN, 2Washington University, St. Louis, MO, 3Washington University in St. Louis, St. Louis, MO

Meeting: ACR Convergence 2023

Keywords: Fibroblasts, Synovial, Micro-RNA, Non-coding RNA, Osteoarthritis, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: High-density lipoprotein (HDL), known for its anti-atherogenic reverse cholesterol transport function, also transports miRNAs between cells, altering cellular function. We found that compared to control subjects, patients with rheumatoid arthritis (RA) – a type of inflammatory arthritis (IA) – have increased plasma HDL-bound miR-1246, which increased macrophage IL-6 expression. Previous reports indicate that HDL is enriched in the synovial fluid of patients with RA versus osteoarthritis (OA). We hypothesize that in IA the higher concentration of synovial HDL promotes joint inflammation by delivering a higher cargo load of miR-1246 to synovial fibroblasts and enhancing the release of inflammatory cytokines. The purpose of this study is to determine if HDL and HDL-miR-1246 is enriched in IA versus OA synovial fluid and increases synovial fibroblast proinflammatory cytokine expression.

Methods: Synovial fluid and plasma were collected consecutively from 15 IA (10 RA and 5 with immune-checkpoint inhibitor-induced IA) and 4 OA patients who underwent arthrocentesis for routine care. Nuclear magnetic resonance was used to measure the synovial fluid and plasma lipoproteins. Synovial fluid HDL was isolated by fast protein liquid chromatography. Synovial fluid miR-1246 and synovial fluid HDL-miR-1246 were measured by qPCR and normalized to a spike-in miRNA and DNA mimic standard to determine miRNA concentration. RA synovial fibroblasts were activated with LPS for 24-hours then washed and treated with a miR-1246 mimic or antagomir for 24-hours. Cellular IL-6 expression was measured by qPCR.

Results: HDL-cholesterol (HDL-C) concentration was similar in IA versus OA plasma (P=0.19). However, synovial fluid HDL was enriched 1.4-fold in IA (29 mg/dl ± 6.1 mg/dl) versus OA (21mg/dl ± 6.9mg/dl) (P=0.04). Similarly, the ratio of synovial fluid to plasma HDL-C was 1.6-fold enriched in IA versus OA patients (P=0.02) (Figure 1). Synovial fluid miR-1246 concentrations were increased 7.9-fold in IA (3000 zmol/uL ± 1860 zmol/uL) versus OA patients (379 zmol/uL ± 126 zmol/uL, P=0.0005). Synovial fluid HDL miR-1246 concentrations were also increased 2.3-fold in IA (183 zmol/ug HDL ± 113 zmol/ug HDL) versus OA patients (80 zmol/ug HDL ± 30 zmol/ug HDL, P=0.049) (Figure 2). Treatment of activated synovial fibroblasts with miR-1246 increased IL-6 expression 2.0-fold (P< 0.0001, Figure 3).

Conclusion: HDL is concentrated in synovial fluid and enriched in miR-1246 in patients with IA versus OA. miR-1246 is proinflammatory to synovial fibroblasts. These data suggest that the HDL may enhance IA synovial inflammation by transport of proinflammatory miRNAs. Future studies will be dedicated to examining HDL-mediated transfer of miR-1246 to synovial fibroblasts and its effect in vivo.

Supporting image 1

Figure 1. NMR-based HDL-C concentration (mg/dL) in plasma (a), synovial fluid (b), and ratio of synovial fluid to plasma (c) in patients with osteoarthritis (OA) versus inflammatory arthritis (IA). Plasma HDL is similar compared IA and OA (P=0.19) (a). Synovial fluid HDL is significantly enriched 1.4-fold in IA versus OA (b). The ratio of synovial fluid to plasma HDL-C was 1.6-fold enriched in IA versus OA (c). HDL-C = high-density lipoprotein – cholesterol. IA = inflammatory arthritis. OA = osteoarthritis. ns= not significant. *P<0.05. Bars = mean, whiskers = standard deviation. Mann-Whitney U test.

Supporting image 2

Figure 2. Concentration of miR_1246 in synovial fluid (a) and purified synovial fluid HDL (b) from patients with osteoarthritis (OA) versus inflammatory arthritis (IA). miR_1246 in synovial fluid is 7.9-fold enriched in IA versus OA (a). miR_1246 in purified synovial fluid HDL is 2.3-fold enriched in IA versus OA (b). SF= synovial fluid. *P<0.05, ***P< 0.001. Bars=mean, whiskers= standard deviation. Mann-Whitney U test.

Supporting image 3

Figure 3. Synovial fibroblasts treated with LPS then miR_1246 expressed 2.0-fold more IL-6 versus LPS alone. Treatment with LPS then an antagomir to block endogenous miR_1246 production did not significantly alter IL-6 expression. IL-6 = interleukin 6. GAPDH = glyceraldehyde_3-phosphate dehydrogenase. LPS = lipopolysaccharide. ****P < 0.0001. Bars = mean, whiskers = standard deviation. T-test.


Disclosures: O. Posey: None; Q. Wu: None; A. Phothisane: None; C. Pham: Insmed, 1, 9; D. Parks: None; A. Akk: None; D. Michell: None; K. Vickers: None; M. Ormseth: None.

To cite this abstract in AMA style:

Posey O, Wu Q, Phothisane A, Pham C, Parks D, Akk A, Michell D, Vickers K, Ormseth M. Synovial Fluid High-density Lipoprotein (HDL)-miR-1246 Is Enriched in Patients with Inflammatory Arthritis Compared to Osteoarthritis and Increases Synovial Fibroblast IL-6 Expression [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/synovial-fluid-high-density-lipoprotein-hdl-mir-1246-is-enriched-in-patients-with-inflammatory-arthritis-compared-to-osteoarthritis-and-increases-synovial-fibroblast-il-6-expression/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/synovial-fluid-high-density-lipoprotein-hdl-mir-1246-is-enriched-in-patients-with-inflammatory-arthritis-compared-to-osteoarthritis-and-increases-synovial-fibroblast-il-6-expression/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology